FTO and metabolic dysfunction-associated steatotic liver disease: Studies on a mouse model of Non-alcoholic fatty liver disease (NAFLD) revealed that betaine supplementation during adolescence rectified the decreased m6A levels and the increased Fto gene expression in response to a high-fat diet, by decreasing de novo lipogenesis and increasing lipolysis, and thus protecting mice from high-fat-induced lipid accumulation in the liver [33].